Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ME-344

Generic Name: ME-344

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₀O_₄

CAS Number: 1374524-68-1

Unique Ingredient Identifier: 843G0TDV51

Overview

ME-344 has been used in trials studying the treatment of Solid Tumors.

Background

ME-344 has been used in trials studying the treatment of Solid Tumors.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Phase 1

Terminated

Posted: 2023/04/21

Sponsor:MEI Pharma, Inc.

ID:NCT05824559

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Early Phase 1

Completed

Posted: 2016/06/21

Sponsor:Centro Nacional de I...

ID:NCT02806817

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Phase 1

Terminated

Posted: 2014/03/31

Sponsor:MEI Pharma, Inc.

ID:NCT02100007

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

Phase 1

Completed

Posted: 2012/03/05

Sponsor:MEI Pharma, Inc.

ID:NCT01544322

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy